USFDA concludes inspection at Emcure Pharma Gujarat facility without any observation
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-10-11 05:34 GMT | Update On 2025-10-11 05:34 GMT
Advertisement
Pune: Emcure Pharma has announced that the United States Food and Drug Administration (US FDA) has concluded an inspection at the Company’s Gujarat manufacturing facility without any observation.
The surveillance inspection was conducted from October 06, 2025 to October 10, 2025.
"This is to inform you that the United States Food and Drug Administration (“US FDA”) had conducted surveillance inspection of Company’s manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka - Lakhtar, District- Surendranagar, Gujarat - 382775, from October 06, 2025 to October 10, 2025," Emcure stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.